The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market size is expected to reach US$ 340 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market. Ursodeoxycholic Acid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cholestyramine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment covered in this report include Teva, AbbVie, Glenmark Pharmaceuticals, Par Pharmaceuticals, Mylan, Sanofi, Novartis, Akorn and Albireo Pharma, etc.
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, Segment by Type:
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market size is expected to reach US$ 340 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market. Ursodeoxycholic Acid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cholestyramine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment covered in this report include Teva, AbbVie, Glenmark Pharmaceuticals, Par Pharmaceuticals, Mylan, Sanofi, Novartis, Akorn and Albireo Pharma, etc.
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, Segment by Type:
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
1.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Overview
1.1.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Scope
1.1.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Status and Outlook
1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2029)
1.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Region (2018-2023)
1.5 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
1.6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
1.6.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
1.6.4 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market by Type
2.1 Introduction
2.1.1 Ursodeoxycholic Acid
2.1.2 Cholestyramine
2.1.3 Rifampicin
2.1.4 Late Stage Pipeline Drugs
2.1.5 Others
2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Type (2018-2029)
3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Breakdown by Application (2018-2029)
4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Competition Analysis by Players
4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2022)
4.3 Date of Key Players Enter into Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
4.4 Global Top Players Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Headquarters and Area Served
4.5 Key Players Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Teva
5.1.1 Teva Profile
5.1.2 Teva Main Business
5.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.1.4 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Teva Recent Developments
5.2 AbbVie
5.2.1 AbbVie Profile
5.2.2 AbbVie Main Business
5.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.2.4 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 AbbVie Recent Developments
5.3 Glenmark Pharmaceuticals
5.3.1 Glenmark Pharmaceuticals Profile
5.3.2 Glenmark Pharmaceuticals Main Business
5.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.3.4 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Par Pharmaceuticals Recent Developments
5.4 Par Pharmaceuticals
5.4.1 Par Pharmaceuticals Profile
5.4.2 Par Pharmaceuticals Main Business
5.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.4.4 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Par Pharmaceuticals Recent Developments
5.5 Mylan
5.5.1 Mylan Profile
5.5.2 Mylan Main Business
5.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.5.4 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Mylan Recent Developments
5.6 Sanofi
5.6.1 Sanofi Profile
5.6.2 Sanofi Main Business
5.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.6.4 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Sanofi Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.7.4 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Akorn
5.8.1 Akorn Profile
5.8.2 Akorn Main Business
5.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.8.4 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Akorn Recent Developments
5.9 Albireo Pharma
5.9.1 Albireo Pharma Profile
5.9.2 Albireo Pharma Main Business
5.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.9.4 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Albireo Pharma Recent Developments
5.10 Mirum Pharmaceuticals
5.10.1 Mirum Pharmaceuticals Profile
5.10.2 Mirum Pharmaceuticals Main Business
5.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
5.10.4 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Mirum Pharmaceuticals Recent Developments
6 North America
6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Dynamics
11.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Trends
11.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
11.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges
11.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
